Nuwellis (NUWE) closed at $5.03 on November 12, 2026, down 9.0% from the previous close, on volume of 25,294 shares (30-day average 1,537,328).
Data as of November 12, 2026.
Nuwellis GAAP EPS of -$5.81, revenue of $2.21M
Seeking Alpha News (Thu, 12-Nov 8:08 AM ET)
Globe Newswire (Thu, 12-Nov 8:00 AM ET)
Here are the major earnings before the open Thursday
Seeking Alpha News (Wed, 11-Nov 6:00 PM ET)
Globe Newswire (Tue, 10-Nov 8:30 AM ET)
Nuwellis files FDA 510(k) to expand Aquadex use to pediatric patients as small as 5 kg
Market Chameleon (Thu, 5-Nov 3:57 AM ET)
Globe Newswire (Thu, 5-Nov 8:30 AM ET)
Nuwellis to Report Third Quarter 2026 Financial Results on November 12
Globe Newswire (Wed, 4-Nov 8:30 AM ET)
Nuwellis Announces Acceptance of Multicenter Pediatric Aquadex Study in Pediatric Nephrology
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Globe Newswire (Thu, 8-Oct 8:30 AM ET)
Globe Newswire (Thu, 1-Oct 8:30 AM ET)
Nuwellis Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
Nuwellis trades on the NASDAQ stock market under the symbol NUWE.
As of November 12, 2026, NUWE stock price declined to $5.03 with 25,294 million shares trading.
NUWE has a beta of 5.51, meaning it tends to be more sensitive to market movements. NUWE has a correlation of 0.11 to the broad based SPY ETF.
NUWE has a market cap of $2.04 million. This is considered a Sub-Micro Cap stock.
Last quarter Nuwellis reported $2 million in Revenue and -$26.64 earnings per share. This fell short of revenue expectation by $-446,000 and missed earnings estimates by -$25.96.
In the last 3 years, NUWE traded as high as $412,120.70 and as low as $2.52.
NUWE has underperformed the market in the last year with a price return of -99.4% while the SPY ETF gained +11.9%. NUWE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -60.4% and -13.0%, respectively, while the SPY returned -1.7% and -1.6%, respectively.
NUWE support price is $4.67 and resistance is $6.39 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NUWE shares will trade within this expected range on the day.
